- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Examining Patient Characteristics from SHINE Study
Further discussion of the SHINE study explores characteristics unique to the trial's patient population.
EP: 1.SHINE Study: Illuminating the Promise of Nusinersen in SMA Treatment
EP: 2.Examining Patient Characteristics from SHINE Study
EP: 3.Highlighting Key Data from the CHERISH and SHINE Studies
EP: 4.Examining Key Findings from NURTURE Study
EP: 5.Relevance of NUTURE Study Findings for Patients, Payers, Providers
EP: 6.Navigating Undefined Parameters for SMA Treatment Coverage
Dr. Crawford discusses the patient characteristics in the context of the EMBRACE, CHAIR, and SHINE studies, focusing on comparing children in the nusinersen study who received the drug versus those who received the sham. The randomization was 2:1, with twice as many receiving the drug. Age ranges and durations on the drug were similar. Notably, it's emphasized that this is the last sham control study in spinal musculature due to ethical concerns. Three approved SMA therapies are highlighted: nusinersen, risdiplam, and zolgensma. The ethical dilemma is underscored, acknowledging the sacrifices of sham patients who contributed to the drug approval process, seen as "wounded warriors" enabling a molecular revolution. The journey, though messy initially, emphasizes the importance of recognizing the challenges and ethical considerations in proving therapy efficacy.
Video synopsis is AI-generated and reviewed by Managed Health Care Executive editorial staff.
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More
